CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2- specific and HLA-DR-restricted manner

Blood

Volumn 92, Issue 9, 1998, Pages 3355-3361

  Yasukawa, Masaki ^a   Ohminami, Hideki ^b   Kaneko, Shin ^b   Yakushijin, Yoshihiro ^b   Nishimura, Yasuharu ^b   Inokuchi, Koiti ^b   Miyakuni, Tsuyoshi ^b   Nakao, Shinji ^b   Kishi, Kenji ^b   Kubonishi, Ichiro ^b   Dan, Kazuo ^b   Fujita, Shigeru ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; FUSION PROTEINS, BCR-ABL; HLA-DR ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; L CELLS (CELL LINE); LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 0032213388     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Shtivelman E, Lifshitz B, Gale RP. Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550, 1985
2. Heisterkamp N, Stam K, Groffen J: Structural organization of the bcrgene and its role in the Ph' translocation. Nature 315:758, 1985
3. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375, 1996
4. Cullis JO, Barrett AJ, Goldman JM, Lechler RI: Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: Studies in antigen-processing defective cell lines. Leukemia 8:165, 1994
5. Bocchia M, Wentworth PA. Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A: Specific binding of leukemia oncogene fusion protein peptides to HLAclass I molecules. Blood 85:2680, 1995
6. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY Sette A, Scheinberg DA; Specific human cellular immunity to bcr-abl oncogenederived peptides. Blood 87:3587, 1996
7. Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R: Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 10:693, 1996
8. Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet J-G, Choppin J: Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 27:2066, 1997
9. BCR-ABL protein by human T cells. Leukemia 9:1344, 1995
10. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522, 1996
11. Pawelec G, Max H, Halder T, Bruserud Ø, Merl A, da Suva P, Kaibacher H: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118, 1996
12. Mannering SI, McKenzie JL, Feamley DB, Hart DNJ: HLA-DR1-restricted bcr-abl (b3a2)-specific CD4 T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 90:290, 1997
13. +. Proc Natl Acad Sci USA 79:2365, 1982
14. Yasukawa M, Zarling JM: Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens. J Immunol 133:422, 1984
15. Tite JP, Janeway CA Jr: Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: la restriction and cognate vs. noncognate interactions in cytolysis. Eur J Immunol 14:878, 1984
16. + human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol 133:754, 1984
17. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337, 1995
18. + T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J Virol 67:6259, 1993
19. + T cells. J Immunol 146:1341, 1991
20. - herpes simplex virusspecific human cytotoxic T cells. J Immunol 143:2051, 1989
21. Carding SR, Lu D, Bottomly K: A polymerase chain reaction assay for the detection and quantitation of cytokine gene expression in small numbers of cells. J Immunol Methods 151:277, 1992
22. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ: Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90:2529, 1997
23. Fujisao S, Matsushita S, Nishi T, Nishimura Y: Identification of HLA-DR9 (DRBl*0901)-binding peptide motifs using a phage fUSE5 random peptide library. Hum Immunol 45:131, 1996
24. Nuchtern JG, Biddison WE, Klausner RD: Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 343:74, 1990
25. Jaraquemada D, Marti M, Long EO: An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med 172:947, 1990
26. Weiss S, Bogen B: MHC class II-restricted presentation of intracellular antigen. Cell 64:767, 1991
27. + T lymphocytes against human melanoma: Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154:772, 1995
28. Oxenius A, Bachmann MF, Mathis D, Benoist C, Zinkernagel RM, Hengartner H: Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection. J Immunol 158:5717, 1997
29. Armstrong TD, Clements VK, Martin BK, Ting JPY, OstrandRosenberg S: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94:6886, 1997
30. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H: Molecular mechanisms of lymphocyte-mediated cytotoxicity and theirrole in immunological protection and pathogenesis in vivo. Annu Rev Immunol 14:207, 1996
31. + T cell-mediated cytotoxicity. J Immunol 152:1127, 1994
32. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara S, Yagita H, Okumura K: Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930, 1994
33. + cytotoxic T cells. Proc Natl Acad Sei USA 91:4185, 1994
34. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP: Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-a in chronic myelogenous leukemia. Blood 89:957, 1997
35. BCR-ABL protein. Proc Natl Acad Sci USA 89:1468, 1992
36. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 93:606, 1996
37. Kern DE, Klamet JP, Jensen MCV, Greenberg PD: Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 136:4303, 1986